Articles related to COGNITIVE HEALTH/MEMORY

Studies show that bipolar disorder patients with severe symptoms demonstrate significant impairment in prospective memory – the ability to remember and execute planned future actions.

Phase 2a clinical trials demonstrate benfotiamine’s ability to enhance synaptic activity while maintaining an excellent safety profile, even at doses exceeding normal thiamine blood levels.

This comprehensive overview of dementia symptoms provides physicians with a practical framework for patient education and early detection. By recognizing these signs early, healthcare providers can initiate timely interventions and support strategies to enhance patient care.

Zunveyl, a prodrug of galantamine, has been formulated to minimize gastrointestinal absorption, potentially addressing common tolerability issues associated with acetylcholinesterase inhibitors in Alzheimer’s treatment.

Amantadine emerges as the pharmacologic agent with the most support for improving cognitive impairment after TBI, while cognitive rehabilitation interventions demonstrate substantial evidence for enhancing neurocognitive function and reducing functional limitations.

A phase 3 clinical trial of buntanetap in early Parkinson’s disease patients demonstrated improvements in motor and cognitive functions, particularly in those with longer disease duration and postural instability.